NOX:
Market Cap:
Price Delay ~20min
Entitlement Offer Prospectus
May/June 2020

ASX Announcements


 
    Corporate Presentation for the Reach Markets Virtual Event  
 
    Ceasing to be a substantial holder  
 
    Change of Director's Interest Notice - FB  
 
    Change in substantial holding - amended  
 
    Change in substantial holding  
 
    Noxopharm Chair Letter to Shareholders  
 
    COVID-19 Trial Program to Commence in Europe  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice - BP  
 
    Change of Director's Interest Notice - FB  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - GK  
 
    Appendix 2A - shares  
 
    Appendix 2A - options  
 
    Pro-rata Non-Renounceable Rights Issue Fully Allocated  
 
    Rights Issue Close Date  
 
    Webcast Overview of ASCO 2020 Annual Meeting NOX Posters  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - ID  
 
    Appendix 3G Adjustment to Option Exercise Prices  
 
    ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer  
 
    Listing Rule 6.22.2 Adjustment to Option Exercise Prices  
 
    Proposed issue of Securities - NOX  
 
    Despatch of Pro Rata Entitlement Offer Documents  
 
    FDA allows Veyonda Pre-IND Submission for COVID-19  
 
    Noxopharm ASCO Abstracts Live  
 
    Appendix 2A  
 
    Entitlement Offer Prospectus  
 
    Entitlement Offer - Letter to Optionholders  
 
    Entitlement Offer - Letter to Ineligible Shareholders  
 
    Entitlement Offer - Letter to Eligible Shareholders  
 
    Proposed issue of Securities - NOX  
 
    $7.9 Million Fully Underwritten Entitlement Offer Announced  
 
    Initial Director's Interest Notice - FB  
 
    Appointment of New Board Member  
 
    Trading Halt  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Noxopharm March 2020 Quarterly Report & Appendix 4C  
 
    Abscopal Responses Achieved in Prostate Cancer  
 
    Pipeline Expands With Potential New Brain Cancer Treatment  
 
    Approval to be sought for COVID-19 Clinical Study in U.S.  
 
    Receipt of cash payment for collateral shares  
 
    Noxopharm trial data to be presented at ASCO 2020  
 
    Updated Noxopharm Virtual Roadshow Corporate Presentation  
 
    Noxopharm Investigating Potential COVID-19 Treatment  
 
    Noxopharm Virtual Roadshow Corporate Presentation  
 
    Initial Director's Interest Notice  
 
    Appointment of New Board Member  
 
    Veyonda Awarded First Allowed Patent Application  
 
    Veyonda Clinical Program Update and Guidance  
 
    LuPIN Prostate Cancer Trial Fully Recruited  
 
    Noxopharm Corporate Presentation February 2020  
 
    Half Year Accounts and Chairman Letter  
 
    Section 708 Certificate  
 
    Appendix 2A  
 
    FDA grants IND approval to Veyonda  
 
    Termination of Convertible Loan  
 
    Section 708 Certificate  
 
    Appendix 2A  
 
    Noxopharm Alliance With GenesisCare  
 
    Proposed issue of Securities - NOX  
 
    $8.1M Financing & Re-Set of Capital Structure  
 
    Pronounced survival benefit in LuPIN interim trial data  
 
    Trading Halt  
 
    LuPIN interim trial data to be presented at ASCO GU 2020  
 
    Lapsing of Unlisted Options  
 
    Appendix 4C - Quarterly Report for The Quarter Ending December 31, 2019  
 
    Noxopharm Non-Deal Roadshow Presentation  
 
    Appendix 3B  
 
    Listing of Nyrada Inc. spin-off on ASX  
 
    Becoming a substantial holder for NYR  
 
    Noxopharm Corporate Presentation  
 
    Ceasing to be a substantial holder  
 
    Change of Director's Interest Notice - GK  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    DARRT-1 Clinical Data Webinar  
 
    Nyrada IPO Offer Fully Subscribed  
 
    Unlisted Options Expiring 18 January 2020  
 
    Lodgement of Nyrada Inc Supplementary Prospectus  
 
    Nyrada Inc Initial Public Offering Opens  
 
    Section 708 Certificate - Notes  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    AU$2.4m Increase to Funding Agreement  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Positive DARRT-1 Data in Late-Stage Prostate Cancer  
 
    Trading Halt  
 
    Lodgement of Nyrada Inc Prospectus - Initial Public Offering  
 
    Lodgement of Nyrada Inc Prospectus - Initial Public Offering - Interactive  
 
    Constitution  
 
    Updated Share Trading Policy  
 
    Results of Meeting  
 
    Noxopharm 2019 AGM Corporate Presentations  
 
    DARRT-1 Interim Data Presented To Conference  
 
    LuPIN Data Being Presented To Conference  
 
    Appointment of Chief Commercial Officer  
 
    Noxopharm October 2019 Newsletter  
 
    Appendix 4C - Quarterly Report for The Quarter Ending September 30, 2019  
 
    Dr Graham Kelly to Assume CEO Role  
 
    Appendix 3B  
 
    Section 708 Certificate  
 
    NOX and Nyrada TechKnow Invest Roadshow Presentations  
 
    Durable Anti-Cancer Effect Confirmed in DARRT-1 Study  
 
    Notice of 2019 Annual General Meeting & Proxy Form  
 
    Potential Fundamental Change in Treatment of Brain Cancer  
 
    New Executive Appointments and Board Change  
 
    Final Director's Interest Notice  
 
    Noxopharm 2019 Annual General Meeting Details  
 
    FNN Interview: The LuPIN trial with Veyonda in prostate cancer  
 
    Further Review Shows Major Clinical Benefits from Veyonda  
 
    Corporate Governance Statement - Appendix 4G  
 
    Corporate Governance Statement  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Annual Report to Shareholders  
 
    Departure of Dr Van Wyk  
 
    Veyonda and Radiotherapy Profiled at Key Oncology Meeting  
 
    Results of Meeting  
 
    NOX EGM Chairman's Address and Presentation  
 
    CHANGE OF DIRECTOR'S INTEREST NOTICE - GK  
 
    CHANGE OF DIRECTOR'S INTEREST NOTICE - GK  
 
    Appendix 4E and Audited Financial Statements FY19  
 
    Addendum to Notice of Extraordinary General Meeting  
 
    More Evidence that Veyonda Enhances RT in Prostate Cancer  
 
    NOX Receives FY19 Federal Government R&D Tax Rebate  
 
    Appendix 3B  
 
    Cleansing Statement  
 
    Pre-Clinical Evidence Confirms Veyonda Abscopal Effect  
 
    Lead Manager Appointed for Proposed Nyrada IPO  
 
    Notice of Extraordinary General Meeting/Proxy Form  
 
    Noxopharm Corporate Update Interview  
 
    Noxopharm August 2019 Corporate Presentation  
 
    NOX Releases Initial Newsletter for Nyrada Subsidiary  
 
    Appendix 4C - Quarterly Report for the quarter ending June 30, 2019  
 
    Appendix 3B  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Section 708 Certificate  
 
    Initial Director's Interest Notice  
 
    Final Director's Interest Notice  
 
    NOX Announces AU$26 Million Funding Facility  
 
    NOX Releases Latest Newsletter  
 
    Board Changes Ahead of Corporate Growth  
 
    LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019  
 
    Conference Hears of Positive Interim Data from LuPIN Trial  
 
    NOX Subsidiary, Nyrada Inc, Receives R&D Rebate  
 
    Noxopharm Corporate Presentation June 2019  
 
    DARRT-1 Study Fully Enrolled  
 
    Promising Data Leads to Expansion of LuPIN Trial  
 
    LuPIN Trial Demonstrates High Rates of Response  
 
    Change of Director's Interest Notice - GK  
 
    Appendix 3B  
 
    DARRT Treatment Has Lasting Disease Control at Six Months  
 
    Veyonda and Immuno-Oncology Effect Explained  
 
    Appendix 4C - Quarterly  
 
    Change in Noxopharm Limited Board Structure  
 
    Idronoxil Confirmed as New Immuno-Oncology Drug  
 
    Veyonda Chemotherapy Enhancement Program to be Expanded  
 
    Securities to be released from Voluntary Escrow  
 
    Updated Top 20 shareholder List  
 
    Appendix 3B  
 
    Section 708 Certificate  
 
    Becoming a substantial holder  
 
    KZA: Kazia sells stake in Noxopharm  
 
    NOX provides update to Nyrada Note Holders  
 
    New Corporate Presentation Released  
 
    Noxopharm to expedite Veyonda Clinical Program  
 
    Appendix 4D and Half Year Accounts  
 
    Change of Director's Interest Notice - GK  
 
    Updated Share Trading Policy  
 
    FNN interview with Nox Chief Medical Officer on Interim Data  
 
    Veyonda and Radiotherapy Delivers Clinical Benefits  
 
    Appendix 3B  
 
    Appendix 4C - quarterly report for the quarter ended December 31, 2018  
 
    Principal Investigator Discusses LuPIN-1 Study  
 
    Change of Director's Interest Notice - GK  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX Receives $3.26M Federal Govt R&D Rebate  
 
    DARRT-1 study advancing on basis of positive clinical data  
 
    NOX announces Positive Data from CEP-1 Study of Veyonda  
 
    Initial Director's Interest Notice  
 
    Results of Meeting  
 
    Appointment of Mr John Moore as Non-Executive Director  
 
    NOX 2018 AGM Presentations  
 
    NOX 2018 AGM Information  
 
    NOX to Present Clinical Data at COSA Annual Meeting  
 
    Corporate Presentation  
 
    Appendix 4C - Quarterly report for the quarter ended September 30, 2018  
 
    NOX makes key executive appointment  
 
    Notice of Annual General Meeting & Proxy Form  
 
    Noxopharm Releases Report on Key Progress of Subsidiary  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Change of Director's Interest Notice - PM  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Change of Registry Address: Automic P/L - Sydney Office  
 
    Annual Report to shareholders  
 
    Corporate Governance Statement - Appendix 4G  
 
    Corporate Governance Statement - 2018  
 
    NOX Subsidiary Announces Important Drug Discovery  
 
    NOX to support expanded LuPIN study  
 
    Appendix 4E and Audited Financial Statements  
 
    Nyrada-Key progress with cholesterol-lowering drug candidate  
 
    VEYONDA - Registered Trade Mark for NOX66  
 
    Change of Director's Interest Notice - GK  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - ID  
 
    Appendix 3B  
 
    Interim NOX66 Radiotherapy Clinical Data  
 
    Appendix 4C- Quarterly report for the quarter ended June 30, 2018  
 
    Securities to be released from Escrow  
 
    Release of DARRT-1 Preliminary Safety Data  
 
    Pre-Clinical data confirms Radio-Enhancing potential  
 
    Noxopharm Corporate Presentation for Public Briefing  
 
    End-of-Study Clinical Data shows benefit of NOX66  
 
    Noxopharm 2018 Mid-Year Investor Briefings  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX to present at American Society of Clinical Oncology  
 
    Change in substantial holding  
 
    Securities to be released from Voluntary Escrow  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Noxopharm 2018 Mid-Year Investor Briefings  
 
    Results of Meeting  
 
    NOX CEO interview updates the company's current R&D program  
 
    NOX CEO interview on near complete NOX66 chemotherapy trial  
 
    NOX CEO interview on Radiotherapy Clinical Programs  
 
    Appendix 4C - quarterly  
 
    St Vincent's Hospital study passes first milestone  
 
    Notice of Extraordinary General Meeting / Proxy Form  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    DARRT-1 Clinical Study commences  
 
    NOX Mid-Year Briefings  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX raises $10.8 M to advance clinical program  
 
    Trading Halt  
 
    Evidence of Abscopal Responses in Patients  
 
    Corporate Presentation - Post Interim Clinical Data Release  
 
    FNN Interview with Noxopharm CEO  
 
    NOX Reports NOX66 Clinical Data  
 
    Trading Halt  
 
    Update accompanying Half Year Report  
 
    Appendix 4D and Half Year Accounts  
 
    NOX closes $4m capital raising for US subsidiary Nyrada Inc  
 
    Appendix 4C - quarterly  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX receives FY17 R&D Tax Rebate  
 
    Kazia Therapeutics Ltd and Noxopharm Ltd  
 
    EOY Guidance on 2018 NOX66 Clinical Development Strategy  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Response to ASX Price Query  
 
    Appendix 3B  
 
    Change of Registered Office  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX Open Briefing Corporate Presentation  
 
    Compassionate use of NOX66 in Patients  
 
    Nyrada Inc Opens Capital Raise - Memorandum Released  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - ID  
 
    Appendix 3B  
 
    Webcast of NOX 2017 AGM  
 
    NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model  
 
    Invitation to Open Briefing  
 
    Results of Meeting  
 
    AGM Presentations  
 
    Clarification of Incorrect Information  
 
    Trading Halt  
 
    NOX 2017 AGM Webcast  
 
    Completion of Transfer of Shares to Nyrada Inc  
 
    Promising Interim Clinical Data for NOX66  
 
    Trading Halt  
 
    1st Patient treated in Lupin Study at St Vincent's Hospital  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    NOX making three presentations at COSA  
 
    Section 708 Certificate  
 
    Appendix 3B  
 
    Results of Meeting  
 
    EGM Presentations  
 
    UNSW collaboration confirms drug designed for stroke victims  
 
    Appendix 4C – Quarterly report for the quarter ended September 30, 2017  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to shareholders  
 
    Update - General Meeting Agenda  
 
    October 2017 Open Briefing Corporate Presentation  
 
    Invitation to Open Briefing  
 
    Establishment of Nyrada Inc. - Extraordinary General Meeting  
 
    Australian NOX66 - Radiotherapy Study Opens  
 
    Establishment of Nyrada Inc.  
 
    Positive Clinical Outcomes for NOX66 at ESMO Conference  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice  
 
    NOX CEO Interview explains recent Brain Cancer Announcement  
 
    Appendix 4E and Audited Financial Statements  
 
    Corporate Governance Statement - Appendix 4G  
 
    Corporate Governance Statement  
 
    Important Brain Cancer Findings for NOX66 Program  
 
    Reinstatement to Official Quotation  
 
    Noxopharm raises $5.5 million to advance clinical program  
 
    Suspension from Official Quotation  
 
    Trading Halt Request  
 
    Trading Halt  
 
    NOX Corporate Presentation ahead of Conference  
 
    Appendix 4C - quarterly  
 
    NOX Research Report prepared by APP Securities  
 
    CEO Interview with FNN - Singapore and HK Roadshow  
 
    New Corporate Presentation  
 
    Noxopharm provides update on NOX66 Clinical Trial Program  
 
    Idronoxil data provides hope to treat secondary brain cancer  
 
    NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment  
 
    New Corporate Presentation  
 
    St Vincents Cancer Study to Commence-NOX66 and Radiotherapy  
 
    NOX makes strategic commitment to treatment of rare cancers  
 
    Noxopharm Mid Year Investor Briefings  
 
    Market Guidance for Next Six Months  
 
    Appendix 4C - quarterly  
 
    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
 
    NOX Files Patent Application on 'Smart' Idronoxil  
 
    Appendix 3B  
 
    NOX and Monash Uni Collaboration Receives Federal Grant  
 
    Noxopharm and UNSW combine on stroke project  
 
    Gold Coast Qld Mid-Year Briefing Details  
 
    Notification of Release of Restricted Securities Escrow  
 
    NOX researching rare Abscopal Response  
 
    Appendix 4D and Half Year Accounts  
 
    NOX Presentation and Interview ASX The CEO Sessions  
 
    Updated Share Trading Policy  
 
    ASX CEO Presentation Feb 2017 slides  
 
    Upcoming Events and Presentations  
 
    Change of Principal Place of Business  
 
    Brain Cancer Study Commences  
 
    First NOX66 Clinical Trial to Commence  
 
    Appendix 4C – Quarterly report for the quarter ended 31 December 2016  
 
    Appointment of New Company Secretary  
 
    Appendix 3B  
 
    Change in substantial holding  
 
    Change of Director's Interest Notice - ID  
 
    Change of Director's Interest Notice - GK  
 
    Market Capitalisation - further update  
 
    Appendix 3B  
 
    Market Capitalisation Update  
 
    Results of Meeting  
 
    Breakthrough in Delivering Idronoxil into Brain  
 
    Corporate Presentation Updated  
 
    Corporate Presentation Providing Clinical Program Guidance  
 
    Medical Advisors Appointed for Extensive Clinical Program  
 
    Change in substantial holding DH  
 
    Appendix 4C - quarterly  
 
    Noxopharm 2016 AGM Sydney Briefing  
 
    Notice of 2016 AGM and 2016 Annual Report  
 
    Corporate Presentation  
 
    Appendix 4G  
 
    Amendment to Preliminary Final Report  
 
    Corporate Presentation for Roadshow  
 
    Preliminary Final Report  
 
    Change in substantial holding  
 
    Change in substantial holding DH  
 
    Noxopharm to Initiate Radiotherapy Clinical Studies  
 
    Change of Director's Interest Notice - GK  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Initial Director's Interest Notice - PM  
 
    Initial Director's Interest Notice - ID  
 
    Initial Director's Interest Notice - GK  
 
    Noxopharm Limited commences trading on ASX  
 
    Performance Share Terms  
 
    Option Terms  
 
    Restricted Securities and Capital Structure  
 
    Securities Trading Policy  
 
    Financial Accounts  
 
    Constitution  
 
    ASX Market Release - Admission to Official List  
 
    Appendix 1A & Information Form and Checklist  
 
    Top 20 Holders  
 
    Distribution Schedule  
 
    Company's Admission Disclosures  
 
    ASX Market Release - Pre-Quotation Disclosure  
 
    Prospectus  
 
    ASX Notice - Admission and Commencement of Quotation